Edwards Lifesciences (EW) Debt to Equity (2009 - 2026)

Edwards Lifesciences' Debt to Equity history runs 18 years deep, the most recent figure standing at $0.06 for Q1 2026.

• In Q1 2026, Debt to Equity fell 1.2% year-over-year to $0.06; the TTM figure through Mar 2026 stood at $0.06 (down 1.2% YoY), while the FY2025 annual figure was $0.06, down 2.56% from the prior year.
• Debt to Equity was $0.06 for Q1 2026 at Edwards Lifesciences, roughly flat from $0.06 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.1 in Q4 2022 to a low of $0.06 in Q2 2025.
• Historically, Debt to Equity has averaged $0.08 across 5 years, with a median of $0.08 in 2024.
• The sharpest annual moves came in 2022 and 2024: Debt to Equity increased 0.6% in 2022, then tumbled 33.15% in 2024.
• A 5-year view of Debt to Equity shows it stood at $0.1 in 2022, then decreased by 13.48% to $0.09 in 2023, then sank by 33.15% to $0.06 in 2024, then slipped by 2.56% to $0.06 in 2025, then advanced by 0.13% to $0.06 in 2026.
• The last three Debt to Equity figures came in at $0.06 (Q1 2026), $0.06 (Q4 2025), and $0.06 (Q3 2025), per Business Quant data.